ENDRA Life Sciences Inc. Balance Sheet
NDRA|4 years of annual SEC 10-K data (FY2017-FY2020)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
ENDRA Life Sciences Inc. had $9M in total assets and $7M in shareholders' equity as of FY2020.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Accounts Receivable | - | - | - | $6.8K |
| Inventory | $589.6K | $113.4K | $59.4K | $191.7K |
| Current Assets | $8.2M | $6.5M | $6.9M | $5.9M |
| PP&E (Net) | $212.2K | $236.3K | $273.2K | $241.5K |
| Total Assets | $8.8M | $7.2M | $7.2M | $6.1M |
| Current Liabilities | $986.7K | $2.1M | $974.6K | $848.2K |
| Shareholders' Equity | $7.2M | $6.2M | $5.3M | $5.3M |